Redeye updates its estimates for 2022 following the Q4 report, and comments on various subjects, ranging from organic growth, net revenue retention, Medrave, Webdoc X/NO, and political risks in the case.
ANNONS
Redeye updates its estimates for 2022 following the Q4 report, and comments on various subjects, ranging from organic growth, net revenue retention, Medrave, Webdoc X/NO, and political risks in the case.